Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Trial Profile

An Open-label, 52-Week, Multicenter Trial Evaluating the Long-term Safety and Tolerability of Centanafadine Sustained-Release Tablets in Adults With Attention-Deficit/Hyperactivity Disorder

Not yet recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Jan 2019

At a glance

  • Drugs Centanafadine (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors Otsuka Pharmaceutical Development & Commercialization
  • Most Recent Events

    • 14 Jan 2019 Planned End Date changed from 1 Mar 2021 to 1 Jun 2021.
    • 14 Jan 2019 Planned primary completion date changed from 1 Mar 2021 to 1 Jun 2021.
    • 14 Jan 2019 Planned initiation date changed from 1 Oct 2018 to 1 Feb 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top